Factors that most influence the decision to use a TNF inhibitor*
| Response (mean) | |
|---|---|
| *Respondents were asked to rank these on a scale of 1–5 from most influential (1) to least or never influential (5) (n = 953). (Online survey, US rheumatologists, April 2005.) | |
| Failure of methotrexate | 1.46 |
| Failure of multiple (>2) disease modifying antirheumatic drugs (DMARDs) | 1.50 |
| Physician global assessment | 1.56 |
| Radiographic erosions or worsening | 1.58 |
| Functional impairment | 1.59 |
| Extra-articular manifestations | 2.38 |
| Published guidelines | 2.56 |
| Formulary restrictions | 2.67 |
| Patient request | 2.82 |
| Managed care guidelines | 3.24 |
| Director consumer advertising | 4.34 |